Matthew Layton
WWAMI Medical Education Program (Spokane) - Departmental Page
layton@wsu.edu - Layton, Matthew
Co-occurring Disorders/Affective Neuroscience/Addiction
Psychostimulant Addiction
Chemical Measurements in Addiction
Circadian/Sleep/Addiction
Clinical Trials
Matt Layton, M.D., Ph.D. Clinical Associate Professor, WWAMI (Washington-Wyoming-Alaska-Montana-Idaho) Medical Education Program, Washington State University-Spokane
Medical Director for the Program of Excellence in the Addictions and Leadership Team Member, Program of Excellence in Rural Mental Health and Substance Abuse Treatment, College of Nursing, Washington State University-Spokane; Program Director, University of Washington Department of Psychiatry & Behavioral Sciences Residency Training Program - Spokane Track.
Dr. Layton completed residency training in Psychiatry at the University of Washington. He is certified by the American Board of Psychiatry and Neurology, and has obtained certification from the United States Drug Enforcement Agency as a buprenorphine provider for the treatment of opioid dependence. His Ph.D. is in Pharmacology, specifically related to glutamate- and gamma-aminobutyric acid (GABA)-mediated redox and oxidative stress phenomena associated with brain injury in rats. Active research projects include the study of neuroactive steroid hormones known to modulate glutamate and GABA receptors during acute smoking cessation, as well as during psychostimulant withdrawal from methamphetamine, in comparison to healthy control subjects.
Heading using the h3 tag
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.